Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.
Ghoshal P, Chitta K, Vujcic S, Gaddy J, Miles K, Stein L, Sher T, Lee K, Chanan-Khan A. Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma. Blood 2009, 114: 2832. DOI: 10.1182/blood.v114.22.2832.2832.Peer-Reviewed Original ResearchTumor necrosis factor-related apoptosis-inducing ligandEntity's Board of DirectorsMultiple myelomaResistant MMTherapeutic optionsCombination treatment of MM cellsBortezomib-resistant multiple myelomaWild typeFactor-related apoptosis-inducing ligandBortezomib-resistant diseaseResistant multiple myelomaTreatment of MM cellsResistance to bortezomibInhibition of tumor cell viabilityApoptosis-inducing ligandCell linesExpression of Bcl-2Limited therapeutic optionsMM cell linesConventional therapeutic agentsTumor cell viabilityBR cellsEnhanced cell killingAnnexin V stainingActivation of caspase-8